July 2024 Insight On Undervalued Small Caps With Insider Buying In The Region

In This Article:

As global markets exhibit mixed signals with the S&P 500 reaching new heights amidst a cooling labor market and falling interest rates, investors are keenly observing shifts in economic indicators that could impact investment decisions. In this context, undervalued small-cap stocks with insider buying present a compelling area for consideration, potentially offering resilience and growth opportunities against broader market volatility.

Top 10 Undervalued Small Caps With Insider Buying

Name

PE

PS

Discount to Fair Value

Value Rating

Dundee Precious Metals

9.1x

3.1x

41.41%

★★★★★★

AtriCure

NA

2.7x

47.85%

★★★★★☆

Titan Machinery

3.9x

0.1x

25.84%

★★★★★☆

Columbus McKinnon

21.2x

1.0x

48.19%

★★★★☆☆

Norconsult

28.0x

1.0x

43.68%

★★★☆☆☆

Citizens & Northern

12.4x

2.8x

39.17%

★★★☆☆☆

Ramaco Resources

13.9x

1.1x

12.03%

★★★☆☆☆

Trifast

NA

0.4x

-46.18%

★★★☆☆☆

Community West Bancshares

18.7x

2.9x

42.25%

★★★☆☆☆

Delek US Holdings

NA

0.1x

-134.46%

★★★☆☆☆

Click here to see the full list of 233 stocks from our Undervalued Small Caps With Insider Buying screener.

Underneath we present a selection of stocks filtered out by our screen.

AddLife

Simply Wall St Value Rating: ★★★★★☆

Overview: AddLife is a company specializing in life science products and services, operating primarily in the Labtech and Medtech sectors with a market capitalization of approximately SEK 9.80 billion.

Operations: Labtech and Medtech are the primary revenue contributors, generating SEK 3.61 billion and SEK 6.20 billion respectively. The company's gross profit margin has shown a slight increase over recent periods, reaching approximately 37.17% by the end of the latest reported period in 2024.

PE: 218.4x

Recently, AddLife has shown a mixed financial landscape, with first-quarter sales rising to SEK 2.57 billion from SEK 2.46 billion year-over-year, yet net income dipped significantly to SEK 62 million from SEK 174 million. Despite this, insider confidence is evident as earnings are projected to surge by over 56% annually. This optimism is underscored by strategic decisions made during their latest board meeting and a modest dividend payout adjustment, reflecting a cautious yet forward-looking management approach in navigating current market challenges.

OM:ALIF B Share price vs Value as at Jul 2024
OM:ALIF B Share price vs Value as at Jul 2024

Vimian Group

Simply Wall St Value Rating: ★★★★★☆

Overview: Vimian Group is a diversified healthcare company, operating across multiple segments including Medtech, Diagnostics, Specialty Pharma, and Veterinary Services with a market capitalization of approximately €1.00 billion.